The Management Board contract with Dr. Andreas Terpin ended on January 31, 2021. After three successful years at Xenios AG, Dr. Terpin is pursuing new projects at Fresenius Medical Care.
As part of this, Mr. Jörg Buschbell and Mr. Stefan Kretzschmar were appointed as members of the Management Board of Xenios AG. Both come from Fresenius Medical Care, the world’s leading provider of products and services for people with kidney diseases, and have already held management positions at Xenios AG for several years. Dr. Jürgen Böhm remains on the Management Board as the third member.
Responsibilities are divided up as follows on the Management Board: Mr. Jörg Buschbell is responsible for sales and operating activities, while Mr. Stefan Kretzschmar focuses on finance. Dr. Jürgen Böhm remains responsible, among other things, for medical management and all quality issues. This newly established leadership will ensure the next important steps towards the success of Fresenius Medical Care and Xenios AG in the field of extracorporeal heart & lung therapies.
On behalf of the company, the Supervisory Board of Xenios AG would like to thank Dr. Terpin most sincerely for his significant contribution to the successful development of Xenios AG in recent years. He leaves behind a well-established and stable company, especially after a very challenging yet successful year in 2020.
Xenios AG – a company of the Fresenius Medical Care Group – is a pioneer in extracorporeal heart and lung support. The Novalung and Medos products offer a wide range of heart and lung support products via a single platform, the Xenios console.
Xenios mission is to improve patient well-being and care. The Novalung therapy aims at a paradigm shift in lung support: enabling the treatment of patients that are more awake, more self-determined and more mobile.
Xenios AG has been part of Fresenius Medical Care, the world’s leading provider of products and services for people with kidney disease since the end of 2016. Xenios complements the group’s portfolio in the area of holistic multi-organ support of FME.
Im Zukunftspark 1
Telefon: +49 (7131) 2706-0
Telefax: +49 (7131) 2706-299
Telefon: +49 (7131) 2706-388
Fax: +49 (7131) 2706-299